
Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), signaling an upward trend in its earnings estimates, with the Zacks Consensus Estimate for 2025 EPS rising 0.1% to $9.70 over the past three months. This upgrade positions DGX in the top 20% of Zacks-covered stocks based on earnings estimate revisions, implying potential near-term stock price appreciation driven by institutional investor response to improved earnings outlooks.
Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), a designation based on a positive trend in earnings estimate revisions. Specifically, the Zacks Consensus Estimate for the company's fiscal year 2025 earnings per share has increased by 0.1% over the last three months, reaching $9.70. This upgrade places DGX in the top 20% of the more than 4,000 stocks covered by the Zacks system, suggesting a quantitative improvement in its earnings outlook. Such revisions are significant as they are closely watched by institutional investors and can influence valuation models, potentially leading to increased buying pressure and near-term stock appreciation. However, it is critical to note that the projected $9.70 EPS for FY2025 represents no year-over-year growth, indicating that the recent positive sentiment stems from a marginal upward revision to a stable, rather than accelerating, earnings forecast.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.85
Ticker Sentiment